Trial Profile
A Phase IB Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Idasanutlin (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 20 Oct 2022 Results published in the Blood
- 02 Sep 2021 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 30 Dec 2020 This trial has been discontinued in France, according to European Clinical Trials Database record.